First  Amendment to Vice President Employment Agreement



 Exhibit 10.14 
 AMENDMENT TO VICE PRESIDENT EMPLOYMENT AGREEMENT 
 This is an
Amendment (“Amendment”) to the Vice President Employment Agreement (“Agreement”) dated and effective June 1, 2005, between Globus Medical, Inc., (“Company”), and Brett Murphy, a resident of
Pennsylvania (the “Vice President”), collectively referred to hereinafter as the “Parties”. A copy of the Agreement is attached hereto as Exhibit A, and is incorporated herein by reference. 

This Amendment is made and entered into by the Parties and effective the 1st day of November, 2006 (“Effective Date”). 
 RECITALS 

 

	 	A.	WHEREAS, the Agreement sets forth certain aspects of Vice President’s at-will employment relationship with Company. 


 

	 	B.	WHEREAS, the Parties have agreed to amend certain aspects of Vice President’s employment relationship set forth in the Agreement, including the compensation
arrangement and scope of duties, and therefore mutually agree and desire to revise the Agreement to reflect these changes. 

  

	 	C.	WHEREAS, in exchange for an in consideration of Vice President’s new territory and compensation arrangement set forth in this Amendment, including a new stock
option grant, Vice President agrees to forfeit the following stock option grants as more fully identified in the Agreement, and agrees the Company is not obligated to give Vice President: (1) 5,000 shares of common stock each on
December 31, 2006 and December 31, 2007; and (2) 40,000 shares of common stock originally granted June 1, 2005. Vice President forever waives any right to these stock option grants, and acknowledges Company has no obligation to
issue the same. 

 NOW, THEREFORE, in consideration of the mutual promises in this Agreement, and other good and
valuable consideration, including the continued employment of Vice President by the Company and the additional compensation received by Vice President from the Company from time to time, the receipt and sufficiency of which are hereby acknowledged,
the parties hereto, intending to be legally bound, hereby agree as follows: 
 Paragraph 1 is revised to read, in its entirety, as
follows: 
  

	 	1.	EMPLOYMENT. The Company hereby employs Vice President, and Vice President hereby accepts employment. Vice President shall serve as the Vice President of United
States Sales – West, upon the terms and conditions hereinafter set forth, and in the territories as assigned by Company. 

 Exhibit A (Territory) is deleted. 







 Paragraph 4 (a), (b), (c) and (d) are revised to read, in their entirety, as follows:

  

	 	4.	COMPENSATION. During the term of this Agreement, Vice President’s compensation shall be determined and paid as follows: 


 

	 	a.	BASE SALARY. Vice President shall receive a base salary of $150,000.00 per year to be paid in accordance with Company’s regular pay schedule, less federal,
state and local payroll taxes and other withholdings legally required or properly requested by Vice President, in accordance with the Company’s regular payroll practices and procedures. 


 

	 	i.	Auto Allowance. Vice President shall receive a monthly auto allowance of $700.00. 


 

	 	b.	QUARTERLY QUOTA BONUS. Vice President will be eligible to receive a bonus of $17,500 per calendar quarter payable contingent upon Vice President’s
achievement of certain sales quotas as defined by and subject to change at the discretion of the Company. 

  

	 	c.	MONTHLY GROWTH BONUS. Vice President will be eligible to receive a monthly bonus based on the percentage of growth in his assigned territories, subject to change
at the discretion of Globus, to be paid as follows: (i) for the first year of this Amendment, 0.75% of growth in sales over the immediately prior year in assigned territories; and (ii) for the second year and any subsequent years of this
Amendment, a minimum of 0.5% of growth in sales over the immediately prior year in assigned territories. 

  

	 	d.	STOCK OPTIONS. Company shall grant to Vice President an option to purchase 350,000 shares of the Company’s Class A common stock, according to the
Notice of Stock Option Grant attached as Exhibit 1 to this Amendment. 

 This Amendment may be executed in
counterparts (and by different parties hereto on different counterparts), each of which shall constitute an original, but all of which when taken together shall constitute a single contract. Delivery of an executed counterpart of a signature page of
this Amendment by telecopy shall be effective as delivery of a manually executed counterpart of this Amendment. 
 [signature
page follows] 

  
 2 








 IN WITNESS WHEREOF, the parties have executed this Amendment to Vice President Employment
Agreement effective as of the day and year first above written. 
  

			
	GLOBUS MEDICAL, INC.
		
	By:	 	 /s/ Dave Demski

	Name: Dave Demski
	Title: CFO
	
	VICE PRESIDENT
	
	 /s/ Brett Murphy

	BRETT MURPHY



  
 3 








 EXHIBIT 1 
 GLOBUS MEDICAL, INC. 
 2003 STOCK PLAN 

NOTICE OF STOCK OPTION GRANT 
 Brett Murphy 
 You have been granted an option to purchase Class A Common
Stock of Globus Medical, Inc. (the “Company”), as follows: 
  

					
	Date of Grant	 	11/1/06
		
	Vesting Commencement Date	 	11/1/06
		
	Exercise Price per Share	 	$0.90
		
	Total Number of Shares Granted	 	350,000
		
	Total Exercise Price	 	$315,000.00
			
	Type of Option:	 	    X    	  	Incentive Stock Option
		 	            	  	Nonstatutory Stock Option
			
	Term/Expiration Date:	 		  	10 Years/ 11/6/16
		
	Vesting Schedule:	 	Subject to accelerated vesting as set forth in the Plan or in the Stock Option Agreement, this Option may be exercised, in whole or in part, in accordance with the
following schedule: 82,638 shares subject to the Option shall vest immediately as of the Date of Grant; thereafter,
1/55th of the remaining 267,362 shares subject to the
Option shall vest at the end of each month subsequent to the Vesting Commencement Date, provided that such optionee remains an employee of the Company as of each such vesting date.
		
	Termination Period:	 	Option may be exercised for up to 90 days after termination of employment or consulting relationship except as set out in Sections 7 and 8 of the Stock Option
Agreement (but in no event later than the Expiration Date); provided that terminations “For Cause” are governed by the Plan, which provides for immediate termination of the Option upon such termination “For
Cause.”


  
 4 








 By your signature and the signature of the Company’s representative below, you and the
Company agree that this option is granted under and governed by the terms and conditions of the Globus Medical, Inc. 2003 Stock Plan (the “Plan”) and the Stock Option Agreement, all of which are attached and made a part of this document.

 Dated:                      

 

							
	OPTIONEE:	  		 	GLOBUS MEDICAL, INC.
				
	 /s/ Brett Murphy
	  		 	By:	 	 /s/ David Demski

				
	 Brett Murphy
	  		 	Name:	 	 David Demski

	Print Name	  		 		 	
		  		 	Title:	 	 CFO



  
 5 








 GLOBUS MEDICAL, INC. 

STOCK OPTION AGREEMENT 
 1. Grant of Option. Globus Medical, Inc., a Delaware corporation (the “Company”), hereby grants to the Optionee named in the Notice of Grant (the “Optionee”), an option (the
“Option”) to purchase a total number of shares of Class B Common Stock (the “Shares”) set forth in the Notice of Grant, at the exercise price per share set forth in the Notice of Grant (the “Exercise Price”) subject to
the terms, definitions and provisions of the Globus Medical, Inc. 2003 Stock Plan (the “Plan”) adopted by the Company, which is incorporated herein by reference. Unless otherwise defined herein, the terms defined in the Plan shall have the
same defined meanings in this Option. 
 If designated an Incentive Stock Option, this Option is intended to qualify as an
Incentive Stock Option as defined in Section 422 of the Code, or any successor provision. 
 2. Exercise of Option.
This Option shall be exercisable during its term in accordance with the Vesting Schedule set out in the Notice of Grant and with the provisions of Section 8 of the Plan as follows: 

(a) Right to Exercise. 
 (i) This Option may not be exercised for a fraction of a share. 
 (ii) In the
event of Optionee’s death, disability or other termination of employment, the exercisability of the Option is governed by Sections 6, 7 and 8 below, subject to the limitation contained in subsection 2(a)(iii). 

(iii) In no event may this Option be exercised after the date of expiration of the term of this Option as set forth in the Notice of
Grant. 
 (b) Method of Exercise. This Option shall be exercisable by written notice (in the form attached hereto as
Exhibit A) which shall state the election to exercise the Option, the number of Shares in respect of which the Option is being exercised, and such other representations and agreements as to the holder’s investment intent with
respect to such shares of Class B Common Stock as may be required by the Company pursuant to the provisions of the Plan. Such written notice shall be signed by the Optionee and shall be delivered in person or by certified mail to the Secretary of
the Company. The written notice shall be accompanied by payment of the Exercise Price. This Option shall be deemed to be exercised upon receipt by the Company of such written notice accompanied by the Exercise Price. 

No Shares will be issued pursuant to the exercise of an Option unless such issuance and such exercise shall comply with all relevant
provisions of law and the requirements of any stock exchange upon which the Shares may then be listed. Assuming such compliance, for income tax purposes the Shares shall be considered transferred to the Optionee on the date on which the Option is
exercised with respect to such Shares. 

  
 6 








 3. Optionee’s Representations. In the event the Shares purchasable pursuant to
the exercise of this Option have not been registered under the Securities Act of 1933, as amended (the “Securities Act”), at the time this Option is exercised, Optionee shall, if required by the Company, concurrently with the exercise of
all or any portion of this Option, deliver to the Company an Investment Representation Statement in the form attached hereto as Exhibit B. 
 4. Method of Payment. Payment of the Exercise Price shall be by any of the following, or a combination thereof, at the election of the Optionee: 

 

	 	a.	cash; 

  

	 	b.	check; or 

  

	 	c.	at the discretion of the Board or Committee, any other method permitted by the Plan. 


5. Restrictions on Exercise. This Option may not be exercised until such time as the Plan and the Shares covered by this Option
have been approved by the stockholders of the Company, or if the issuance of such Shares upon such exercise or the method of payment of consideration for such shares would constitute a violation of any applicable federal or state securities or other
law or regulation, including any rule under Part 207 of Title 12 of the Code of Federal Regulations (“Regulation G”) as promulgated by the Federal Reserve Board. As a condition to the exercise of this Option, the Company may
require Optionee to make any representation and warranty to the Company as may be required by any applicable law or regulation. 

6. Termination of Relationship. In the event of termination of Optionee’s employment or consulting relationship with the
Company, Optionee may, to the extent otherwise so entitled at employee or date of such termination (the “Termination Date”), exercise this Option during the Termination Period set out in the Notice of Grant. To the extent that Optionee was
not entitled to exercise this Option at the date of such termination, or if Optionee does not exercise this Option within the time specified herein, the Option shall terminate. 

7. Disability of Optionee. Notwithstanding the provisions of Section 6 above, in the event of termination of Optionee’s
consulting or employment relationship or as a result of his total and permanent disability (as defined in Section 22(e)(3) of the Code or any successor provision), Optionee may, but only within twelve (12) months from the date of
termination of employment or consulting relationship (but in no event later than the date of expiration of the term of this Option as set forth in Section 10 below), exercise this Option to the extent Optionee was entitled to exercise it at the
date of such termination. To the extent that Optionee was not entitled to exercise the Option at the date of termination, or if Optionee does not exercise such Option (which Optionee was entitled to exercise) within the time specified herein, the
Option shall terminate. 

  
 7 








 8. Death of Optionee. In the event of the death of Optionee during the term of this
Option and, with respect to a Consultant, during such Consultant’s continuing consulting relationship with the Company or within 90 days of termination of Consultant’s relationship with the Company and, with respect to an employee, during
such employee’s employment relationship with the Company or within 90 days of termination of such employee’s relationship with the Company, the Option may be exercised, at any time within twelve (12) months following the date of
termination (but in no event later than the date of expiration of the term of this Option as set forth in Section 10 below), by Optionee’s estate or by a person who acquired the right to exercise the Option by bequest or inheritance, but
only to the extent of the right to exercise that Optionee was entitled to at the date of death. 
 9. Nontransferability of
Option. This Option may not be transferred in any manner otherwise than by will or by the laws of descent or distribution and may be exercised during the lifetime of Optionee only by Optionee. The terms of this Option shall be binding upon the
executors, administrators, heirs, successors and assigns of the Optionee. 
 10. Term of Option. This Option may be
exercised only within the term set out in the Notice of Grant and the Plan, and may be exercised during such term only in accordance with the Plan and the terms of this Option. The limitations set out in Section 7 of the Plan regarding Options
designated as Incentive Stock Options and Options granted to more than ten percent (10%) stockholders shall apply to this Option. 
 11. Taxation Upon Exercise of Option. Optionee understands that, upon exercising a Nonstatutory Stock Option, he or she will recognize income for tax purposes in an amount equal to the excess of
the then fair market value of the Shares over the exercise price. If the Optionee is an employee, the Company will be required to withhold from Optionee’s compensation, or collect from Optionee and pay to the applicable taxing authorities an
amount equal to a percentage of this compensation income. Additionally, the Optionee may at some point be required to satisfy tax withholding obligations with respect to the disqualifying disposition of an Incentive Stock Option. The Optionee shall
satisfy his or her tax withholding obligation arising upon the exercise of this Option by one or some combination of the following methods: (i) by cash payment, or (ii) out of Optionee’s current compensation. 

12. Tax Consequences. Set forth below is a brief summary as of the date of this Option of some of the United States federal tax
consequences of exercise of this Option and disposition of the Shares. THIS SUMMARY IS NECESSARILY INCOMPLETE, AND THE TAX LAWS AND REGULATIONS ARE SUBJECT TO CHANGE. THIS SUMMARY DOES NOT PURPORT TO ADDRESS OR SUMMARIZE THE STATE, LOCAL OR FOREIGN
TAX CONSEQUENCES OF EXERCISE OF THIS OPTION OR DISPOSITION OF THE SHARES. OPTIONEE SHOULD CONSULT A TAX ADVISER BEFORE EXERCISING THIS OPTION OR DISPOSING OF THE SHARES. 
 (a) Exercise of ISO. If this Option qualifies as an ISO, there will be no regular federal income tax liability upon the exercise of the Option, although the excess, if any, of the fair market value
of the Shares on the date of exercise over the Exercise Price will be treated as an item of adjustment to the alternative minimum tax for federal tax purposes in the year of exercise and may subject the Optionee to the alternative minimum tax.


  
 8 








 (b) Exercise of Nonstatutory Stock Option. If this Option does not qualify as an ISO,
there may be a regular federal income tax liability upon the exercise of the Option. The Optionee will be treated as having received compensation income (taxable at ordinary income tax rates) equal to the excess, if any, of the fair market value of
the Shares on the date of exercise over the Exercise Price and the Company will qualify for a deduction in the same amount, subject to the requirement that the compensation be reasonable. If Optionee is an employee, the Company will be required to
withhold from Optionee’s compensation or collect from Optionee and pay to the applicable taxing authorities an amount equal to a percentage of this compensation income at the time of exercise. 

(c) Disposition of Shares. In the case of an NSO, if Shares are held for at least one year, any gain realized on disposition of
the Shares will be treated as long-term capital gain for federal income tax purposes. In the case of an ISO, if Shares transferred pursuant to the Option are held for at least one year after exercise and are disposed of at least two years after the
Date of Grant, any gain realized on disposition of the Shares will also be treated as long-term capital gain for federal income tax purposes. If Shares purchased under an ISO are disposed of within one-year after exercise or within two years after
the Date of Grant, any gain realized on such disposition will be treated as compensation income (taxable at ordinary income rates) in an amount equal to the excess of the lesser of (1) the fair market value of the Shares on the date of
exercise, or (2) the sale price of the Shares over the Exercise Price paid for those shares. The Company will also be allowed a deduction equal to any such amount recognized, subject to the requirement that the compensation be reasonable.

 (d) Notice of Disqualifying Disposition of ISO Shares. If the Option granted to Optionee herein is an ISO, and if
Optionee sells or otherwise disposes of any of the Shares acquired pursuant to the ISO on or before the later of (1) the date two years after the Date of Grant, or (2) the date one year after the date of exercise, the Optionee shall
immediately notify the Company in writing of such disposition. Optionee agrees that Optionee may be subject to income tax withholding by the Company on the compensation income recognized by the Optionee from the early disposition by payment in cash
or out of the current earnings paid to the Optionee. 
 13. Company’s SAR Option upon Termination prior to IPO.
Notwithstanding anything to the contrary in Section 2 hereof, in the event that the Company receives a notice from Optionee requesting exercise of the option after or in connection with the termination of such optionee’s employment with
the Company at any time prior to the first registration statement for the sale of its Class B Common Stock to the public under the Securities Act, the Company shall have the irrevocable, exclusive right for a period of ninety (90) days from the
date of such notice (the “SAR Option”), to cause the option to be surrendered in exchange for payment of an amount (the “SAR Amount”) equal to the difference between the purchase price payable for the Shares hereunder and the
fair market value of the shares as of the date of termination of the Optionee’s status as an employee. The “fair market value” shall be deemed to be the fair value of the Class B Common Stock as determined by the Board of Directors
after 

  
 9 








 
taking into consideration all factors that it deems appropriate, including, without limitation, recent sale and offer prices on the Class B Common Stock in private transactions negotiated at
arms’ length, but determined without regard to any restriction on the Shares other than a restriction that, by its terms will never lapse. The SAR Amount shall be paid, at the Company’s option, (i) by delivery of a check in the amount
of the SAR Amount, (ii) by cancellation of any amount of the Optionee’s indebtedness to the Company equal to the SAR Amount, or (iii) by a combination of (i) and (ii) so that the combined payment and cancellation of
indebtedness equals such SAR Amount. 
 OPTIONEE ACKNOWLEDGES AND AGREES THAT THE EXERCISE OF THE COMPANY’S SAR OPTION WILL
CONSTITUTE A DISQUALIFYING DISPOSITION OF THE OPTION SO THAT THE SAR AMOUNT RECEIVED WILL BE TREATED FOR TAX PURPOSES AS ORDINARY INCOME TO THE OPTIONEE. WITH THIS UNDERSTANDING, OPTIONEE AFFIRMS THE GRANT OF THE SAR OPTION TO THE COMPANY IN
CONNECTION WITH OPTIONEE’S RECEIPT OF THE OPTION. OPTIONEE ACKNOWLEDGES AND AGREES THAT THE VESTING OF SHARES PURSUANT TO THE OPTION HEREOF IS EARNED ONLY BY CONTINUING CONSULTANCY OR EMPLOYMENT AT THE WILL OF THE COMPANY (NOT THROUGH THE ACT
OF BEING HIRED, BEING GRANTED THIS OPTION OR ACQUIRING SHARES HEREUNDER). OPTIONEE FURTHER ACKNOWLEDGES AND AGREES THAT NOTHING IN THIS AGREEMENT, NOR IN THE COMPANY’S STOCK OPTION PLAN, WHICH IS INCORPORATED HEREIN BY REFERENCE, SHALL CONFER
UPON OPTIONEE ANY RIGHT WITH RESPECT TO CONTINUATION OF EMPLOYMENT OR CONSULTANCY BY THE COMPANY, NOR SHALL IT INTERFERE IN ANY WAY WITH OPTIONEE’S RIGHT OR THE COMPANY’S RIGHT TO TERMINATE OPTIONEE’S EMPLOYMENT OR CONSULTANCY AT ANY
TIME, WITH OR WITHOUT CAUSE. 
 14. Company’s Right of First Refusal. Before any Shares held by Optionee or any
transferee (either being sometimes referred to herein as the “Holder”) may be sold or otherwise transferred (including transfer by gift or operation of law), the Company or its assignee(s) shall have a right of first refusal to purchase
the Shares on the terms and conditions set forth in this Section (the “Right of First Refusal”). 
 (a) Notice of
Proposed Transfer. The Holder of the Shares shall deliver to the Company a written notice (the “Notice”) stating: (i) the Holder’s bona fide intention to sell or otherwise transfer such Shares; (ii) the name of each
proposed Optionee or other transferee (“Proposed Transferee”); (iii) the number of Shares to be transferred to each Proposed Transferee; and (iv) the bona fide cash price or other consideration for which the Holder proposes to
transfer the Shares (the “Offered Price”), and the Holder shall offer the Shares at the Offered Price to the Company or its assignee(s). 
 (b) Exercise of Right of First Refusal. At any time within thirty (30) days after receipt of the Notice, the Company and/or its assignee(s) may, by giving written notice to the Holder, elect
to purchase all, but not less than all, of the Shares proposed to be transferred to any one or more of the Proposed Transferees, at the purchase price determined in accordance with subsection (c) below. 

  
 10 









 (c) Purchase Price. The purchase price (“Purchase Price”) for the Shares
purchased by the Company or its assignee(s) under this Section shall be the Offered Price. If the Offered Price includes consideration other than cash, the cash equivalent value of the noncash consideration shall be determined by the Board of
Directors of the Company in good faith. 
 (d) Payment. Payment of the Purchase Price shall be made, at the option of the
Company or its assignee(s), in cash (by check), by cancellation of all or a portion of any outstanding indebtedness of the Holder to the Company (or, in the case of repurchase by an assignee, to the assignee), or by any combination thereof within 30
days after receipt of the Notice or in the manner and at the times set forth in the Notice. 
 (e) Holder’s Right to
Transfer. If all of the Shares proposed in the Notice to be transferred to a given Proposed Transferee are not purchased by the Company and/or its assignee(s) as provided in this Section, then the Holder may sell or otherwise transfer such
Shares to that Proposed Transferee at the Offered Price or at a higher price, provided that such sale or other transfer is consummated within 90 days after the date of the Notice and provided further that any such sale or other transfer is effected
in accordance with any applicable securities laws and the Proposed Transferee agrees in writing that the provisions of this Section shall continue to apply to the Shares in the hands of such Proposed Transferee. If the Shares described in the Notice
are not transferred to the Proposed Transferee within such period, a new Notice shall be given to the Company, and the Company and/or its assignees shall again be offered the Right of First Refusal before any Shares held by the Holder may be sold or
otherwise transferred. 
 (f) Exception for Certain Family Transfers. Anything to the contrary contained in this Section
notwithstanding, the transfer of any or all of the Shares during the Optionee’s lifetime or on the Optionee’s death by will or intestacy to the Optionee’s immediate family or a trust for the benefit of the Optionee’s immediate
family shall be exempt from the provisions of this Section. “Immediate Family” as used herein shall mean spouse, lineal descendant or antecedent, father, mother, brother or sister. In such case, the transferee or other recipient
shall receive and hold the Shares so transferred subject to the provisions of this Section, and there shall be no further transfer of such Shares except in accordance with the terms of this Section. 

(g) Termination of Right of First Refusal. The Right of First Refusal shall terminate as to any Shares 90 days after the first
sale of Class B Common Stock of the Company to the general public pursuant to a registration statement filed with and declared effective by the Securities and Exchange Commission under the Securities Act. 

15. Restrictive Legends and Stop-Transfer Orders. 
 (a) Legends. Optionee understands and agrees that the Company shall cause the legends set forth below or legends substantially equivalent thereto, to be placed upon any certificate(s) evidencing
ownership of the Shares together with any other legends that may be required by state or federal securities laws: 
 THE
SECURITIES REPRESENTED HEREBY HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933 (THE “ACT”) AND MAY NOT BE OFFERED, SOLD OR OTHERWISE TRANSFERRED, PLEDGED OR HYPOTHECATED UNLESS AND UNTIL REGISTERED UNDER THE ACT OR, IN THE OPINION
OF COUNSEL IN FORM AND SUBSTANCE SATISFACTORY TO THE ISSUER OF THESE SECURITIES, SUCH OFFER, SALE OR TRANSFER, PLEDGE OR HYPOTHECATION IS IN COMPLIANCE THEREWITH. 

  
 11 









 THE SHARES REPRESENTED BY THIS CERTIFICATE ARE SUBJECT TO CERTAIN RESTRICTIONS ON TRANSFER
AND RIGHT OF FIRST REFUSAL OPTIONS HELD BY THE ISSUER OR ITS ASSIGNEE(S) AS SET FORTH IN THE ISSUER’S STOCK PLAN AND THE STOCK OPTION AGREEMENT RELATING TO THESE SHARES, COPIES OF WHICH MAY BE OBTAINED AT THE PRINCIPAL OFFICE OF THE ISSUER.
SUCH TRANSFER RESTRICTIONS AND RIGHT OF FIRST REFUSAL ARE BINDING ON TRANSFEREES OF THESE SHARES. 
 (b) Stop-Transfer
Notices. Optionee agrees that, in order to ensure compliance with the restrictions referred to herein, the Company may issue appropriate “stop transfer” instructions to its transfer agent, if any, and that, if the Company transfers its
own securities, it may make appropriate notations to the same effect in its own records. 
 (c) Refusal to Transfer.
The Company shall not be required (i) to transfer on its books any Shares that have been sold or otherwise transferred in violation of any of the provisions of this Agreement or (ii) to treat as owner of such Shares or to accord the right
to vote or pay dividends to any Optionee or other transferee to whom such Shares shall have been so transferred. 
 16.
Successors and Assigns. The Company may assign any of its rights under this Agreement to single or multiple assignees, and this Agreement shall inure to the benefit of the successors and assigns of the Company. Subject to the restrictions on
transfer herein set forth, this Agreement shall be binding upon Optionee and his or her heirs, executors, administrators, successors and assigns. 
 17. Interpretation. Any dispute regarding the interpretation of this Agreement shall be submitted by Optionee or by the Company forthwith to the Company’s Board of Directors or the Committee
that administers the Plan, which shall review such dispute at its next regular meeting. The resolution of such a dispute by the Board or committee shall be final and binding on the Company and on Optionee. 

  
 12 









 18. Governing Law; Severability. This Agreement shall be governed by and construed in
accordance with the laws of the State of Delaware excluding that body of law pertaining to conflicts of law. Should any provision of this Agreement be determined by a court of law to be illegal or unenforceable, the other provisions shall
nevertheless remain effective and shall remain enforceable. 
 19. Notices. Any notice required or permitted hereunder
shall be given in writing and shall be deemed effectively given upon personal delivery or upon deposit in the United States mail by certified mail, with postage and fees prepaid, addressed to the other party at its address as shown below beneath its
signature, or to such other address as such party may designate in writing from time to time to the other party. 
 20.
Further Instruments. The parties agree to execute such further instruments and to take such further action as may be reasonably necessary to carry out the purposes and intent of this Agreement. 

21. 2003 Stock Plan. Optionee acknowledges receipt of a copy of the Plan and represents that Optionee is familiar with the terms
and provisions thereof, and hereby accepts this Option subject to all of the terms and provisions thereof. Optionee has reviewed the Plan and this Option in their entirety, has had an opportunity to obtain the advice of counsel prior to executing
this Option and fully understands all provisions of the Option. Optionee hereby agrees to accept as binding, conclusive and final all decisions or interpretations of the Board or Committee upon any questions arising under the Plan or this Option.


*        *        *      
  *        *        *        *        *       
 *        * 

  
 13 









 EXHIBIT A 

GLOBUS MEDICAL, INC. 
 EXERCISE NOTICE 
 Globus Medical, Inc. 

			
	  
	  	
	  
	  	

 Attention: Secretary 
 1. Exercise of Option. Effective as of today, the undersigned (“Optionee”) hereby elects to exercise Optionee’s option to purchase
            shares of the Class B Common Stock (the “Shares”) of Globus Medical, Inc. (the “Company”) under and pursuant to the Company’s 2003 Stock Plan, as
amended (the “Plan”) and the      Incentive      Nonstatutory Stock Option Agreement dated             ,
            (the “Option Agreement”). The purchase price for the Shares shall be $        as required by the Option Agreement. Optionee
herewith delivers to the Company the full Exercise Price for the Shares. 
 2. Representations of Optionee. Optionee
acknowledges that Optionee has received, read and understood the Plan and the Option Agreement and agrees to abide by and be bound by their terms and conditions. Optionee represents that Optionee is purchasing the Shares for Optionee’s own
account for investment and not with a view to, or for sale in connection with, a distribution of any of such Shares. 
 3.
Compliance with Securities Laws. Optionee understands and acknowledges that the Shares have not been registered under the Securities Act of 1933, as amended (the “Securities Act”), and, notwithstanding any other provision of the
Option Agreement to the contrary, the exercise of any rights to purchase any Shares is expressly conditioned upon compliance with the Securities Act, all applicable state securities laws and all applicable requirements of any stock exchange or over
the counter market on which the Company’s Class B Common Stock may be listed or traded at the time of exercise and transfer. Optionee agrees to cooperate with the Company to ensure compliance with such laws. 

4. Federal Restrictions on Transfer. Optionee understands that the Shares have not been registered under the Securities Act
and therefore cannot be resold and must be held indefinitely unless they are registered under the Securities Act or unless an exemption from such registration is available and that the certificate(s) representing the Shares may bear a legend to
that effect. Optionee understands that the Company is under no obligation to register the Shares and that an exemption may not be available or may not permit Optionee to transfer Shares in the amounts or at the times proposed by Optionee.
Specifically, Optionee has been advised that Rule 144 promulgated under the Securities Act, which permits certain resales of unregistered securities, is not presently available with respect to the Shares and, in any event requires that the
Shares be paid for and then be held for at least one year (and in some cases two years) before they may be resold under Rule 144. 

  
 14 









 5. Rights as Stockholder. Until the stock certificate evidencing such Shares is
issued (as evidenced by the appropriate entry on the books of the Company or of a duly authorized transfer agent of the Company), no right to vote or receive dividends or any other rights as a stockholder shall exist with respect to the optioned
Shares, notwithstanding the exercise of the Option. The Company shall issue (or cause to be issued) such stock certificate promptly after the Option is exercised. No adjustment will be made for a dividend or other right for which the record date is
prior to the date the stock certificate is issued, except as provided in Section 13 of the Plan. 
 Optionee shall enjoy
rights as a stockholder until such time as Optionee disposes of the Shares or the Company and/or its assignee(s) exercises the Right of First Refusal pursuant to the Option Agreement. Upon such exercise, Optionee shall have no further rights as a
holder of the Shares so purchased except the right to receive payment for the Shares so purchased in accordance with the provisions of this Agreement, and Optionee shall forthwith cause the certificate(s) evidencing the Shares so purchased to be
surrendered to the Company for transfer or cancellation. 
 6. Tax Consultation. Optionee understands that Optionee may
suffer adverse tax consequences as a result of Optionee’s purchase or disposition of the Shares. Optionee represents that Optionee has consulted with any tax consultants Optionee deems advisable in connection with the purchase or disposition of
the Shares and that Optionee is not relying on the Company for any tax advice. 
 7. Entire Agreement. The Plan and
Notice of Grant/Option Agreement are incorporated herein by reference. This Exercise Notice, the Plan and the Notice of Grant/Option Agreement and any Investment Representation statement executed and delivered to Company by Optionee shall constitute
the entire agreement of the parties and supersede in their entirety all prior undertakings and agreements of the Company and Optionee with respect to the subject matter hereof, and is governed by Delaware law except for that body of law pertaining
to conflict of laws. 
  

									
	Submitted by:	 		 	Accepted by:
			
	OPTIONEE:	 		 	Globus Medical, Inc.
				
	  
	 		 	By:	  	  

		 		 		 	Name:	  	  

		 		 		 	Title:	  	  

					
	Address:	 	  
	 		 	Address:	  	  

	  
	 		 	  

	  
	 		 	  



  
 15 









 EXHIBIT B 

INVESTMENT REPRESENTATION STATEMENT 
  

							
	OPTIONEE	 	:	    	  
	  	
				
	COMPANY	 	:	    	Globus Medical, Inc.	  	
				
	SECURITY	 	:	    	Class B Common Stock	  	
				
	AMOUNT	 	:	    	                    Shares	  	

 In connection with the purchase of the above-listed Securities, I, the Optionee, represent to the Company the following.

 1. Optionee is aware of the Company’s business affairs and financial condition and has acquired sufficient information
about the Company to reach an informed and knowledgeable decision to acquire the securities. Optionee is purchasing the securities for investment for Optionee’s own account only and not with a view to, or for resale in connection with, any
“distribution” thereof within the meaning of the Securities Act of 1933, as amended (the “Securities Act”). 

2. Optionee understands that the securities have not been registered under the Securities Act in reliance upon a specific exemption
therefrom, which exemption depends upon, among other things, the bona fide nature of Optionee’s investment intent as expressed herein. 
 3. Optionee further understands that the securities must be held indefinitely unless subsequently registered under the Securities Act or unless an exemption from registration is available. Moreover,
Optionee understands that the Company is under no obligation to register the securities. In addition, Optionee understands that the certificate evidencing the securities will be imprinted with a legend that prohibits the transfer of the securities
unless they are registered or such registration is not required in the opinion of counsel for the Company. 
 4. Optionee is
familiar with the provisions of Rules 144, 144(k) and 701, promulgated under the Securities Act, that permit limited public resale of “restricted securities” acquired, directly or indirectly, from the issuer thereof (or from an affiliate
of such issuer) in a nonpublic offering, subject to the satisfaction of certain conditions. 
 In the event the Company becomes
subject to the reporting requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), the securities exempt under Rule 701 may be resold by the Optionee 90 days thereafter, subject to
the satisfaction of certain of the conditions specified by Rule 144, including: (a) the sale being made through a broker in an unsolicited “broker’s 

  
 16 









 
transaction” or in transactions directly with a market maker (as that term is defined under the Exchange Act); and (b) in the case of an affiliate, the availability of certain public
information about the Company, and the amount of securities being sold during any three-month period not exceeding the limitations specified in Rule 144(e), if applicable. 
 If the purchase of the securities does not qualify under Rule 701 at the time of purchase, then the securities may be resold by the Optionee in certain limited circumstances subject to the provisions of
Rule 144, which require: (a) the availability of certain public information about the Company; (b) the resale occurring not less than one year after the party has purchased, and made full payment (within the meaning of Rule 144) for, the
securities to be sold; and (3) in the case of an affiliate, or of a nonaffiliate who has held the securities less than two years, the sale being made through a broker in an unsolicited “broker’s transaction” or in transactions
directly with a market maker (as that term is defined under the Exchange Act) and the amount of securities being sold during any three-month period not exceeding the specified limitations. 

If all of the requirements of Rule 144 are not satisfied, Optionee may be able to sell the securities without registration pursuant to
the exemption contained in Rule 144(k), provided that the resale occurs not less than two years after the party has purchased, and made full payment (within the meaning of Rule 144) for, the securities. 

5. Optionee further understands that at the time Optionee wishes to sell the securities there may be no public market upon which to make
such a sale, and that, even if such a public market then exists, the Company may not be satisfying the current public information requirements of Rules 144 or 701, and that, in such event, Optionee would be precluded from selling the securities
under Rules 144 or 701 even if the one-year minimum holding period had been satisfied; however, Optionee may be able to sell the securities pursuant to the exemptions contained in Rule 144(k) if the two-year holding period has been satisfied.

 6. Optionee further understands that in the event all of the applicable requirements of Rules 144, 144(k) or 701 are not
satisfied, registration under the Securities Act or some registration exemption will be required; and that, notwithstanding the fact that Rules 144, 144(k) and 701 are not exclusive, the Staff of the SEC has expressed its opinion that persons
proposing to sell private placement securities other than in a registered offering and otherwise than pursuant to Rules 144, 144(k) or 701 will have a substantial burden of proof in establishing that an exemption from registration is available for
such offers or sales, and that such persons and their brokers who participate in such transactions do so at their own risk. 
  

					
	Date	 		  	Signature of Optionee:
			
	  
	 		  	  



  
 17